Abscess

Researchers are evaluating non-surgical treatment options for patients with stage III or IV periodontitis who have specific Class II buccal and/or lingual furcation defects in their mandibular and maxillary molars. This prospective, randomized, single-blinded clinical trial uses a split-mouth design to compare treatments and is conducted at Riga Stradins University Institute of Stomatology in Latvia. Patients receive detailed oral hygiene instructions before treatment begins to ensure proper care. The study compares two treatments: the test side receives an oscillating chitosan brush combined with enamel matrix derivatives, while the control side receives the oscillating chitosan brush alone. Treatment is applied to furcation defects at baseline. The trial includes a 12-week re-evaluation period after baseline treatment. Biofilm and gingival crevicular fluid samples are collected at baseline and again at 4 weeks to monitor biological changes. Participants undergo clinical assessments including bleeding on probing, probing pocket depth, clinical attachment level, and furcation involvement measurements at baseline and 12 weeks. Proteomic and microbiological analyses of gingival fluid and plaque samples are performed at baseline and 4 weeks. Patient comfort is measured using a visual analog scale at baseline. The trial involves follow-up visits to monitor periodontal status and treatment effects over 12 weeks.

Researchers are evaluating the safety and effectiveness of a device called RD2 Ver.02 compared to a control treatment for managing transsphincteric and long intersphincteric anal fistulas. The study aims to assess the complication rate within 6 months, recurrence rates at 12 months after treatment, and the incidence of perirectal infection by 6 months. This is a prospective, multi-center, double-blind, randomized controlled trial conducted by RedDress Ltd. Participants will be randomly assigned to one of two groups. Both groups will undergo debridement of the fistula tract, suturing of the internal opening, and a water leak test to ensure sealing. In the treatment group, the patient's own coagulating blood (RD2 Ver.02) will be applied inside the fistula tract to serve as a provisional matrix. In the control group, the blood sample will be discarded, and saline will be applied instead. Treatments are performed in the operating room. Participants will be monitored for healing and complications through 6 to 12 months post-treatment. The primary outcome is the combined healing rate of anal fistulas at 6 months. Secondary outcomes include clinical recurrence at 12 months and incidence of perirectal infections at 6 months. Blood samples, clinical evaluations, and imaging (pelvic MRI) are used to assess eligibility and monitor safety and efficacy. The trial will continue enrollment and follow-up until June 2028.

Researchers are evaluating a deep learning-based model to predict infections caused by multidrug-resistant Klebsiella pneumoniae in patients with liver abscess, an infection of the abdomen with significant mortality risk. The study aims to improve early detection of resistant bacteria using clinical data and imaging to guide better treatment decisions, addressing challenges due to resistance and prior antibiotic use. Liver abscesses caused by Klebsiella pneumoniae have become more common, especially in China, making this research important for managing infections effectively. This observational study collects clinical features, laboratory results, and CT images from patients with pyogenic liver abscesses confirmed by surgery or interventional procedures. Patients undergo abdominal enhanced CT scans before their treatment. The study compares cases with resistant and non-resistant bacterial infections to develop and evaluate a predictive model for multidrug-resistant infections based on this combined data. During the study, researchers obtain bacterial cultures and drug resistance test results within the first week before any surgical or interventional treatment, up to 4 weeks. They use this information to validate the model's accuracy in identifying resistant bacteria early. Participants contribute their clinical data and imaging to this research without receiving experimental treatment. The study continues until March 2025, aiming to improve infection management through advanced prediction methods.

Chronic subdural hematoma (CSDH) is a common condition often treated by neurosurgical evacuation and drainage of the hematoma. This research aims to compare two drainage methods after surgery: 24 hours of active subperiosteal drainage versus 24 hours of passive subdural drainage. The study is a nationwide, randomized clinical trial conducted across all neurosurgical units in Denmark to evaluate if active drainage is not worse than passive drainage in terms of safety and recurrence. Participants will be adults with symptomatic unilateral CSDH undergoing single burr hole evacuation. Before surgery, patients will be randomly assigned to receive either 24 hours of active subperiosteal drainage or 24 hours of passive subdural drainage. Both drainage methods are already in use, but a direct comparison has not been done. The trial will monitor patients for 90 days post-surgery to assess outcomes. During the study, participants will be evaluated for mortality and recurrence of CSDH requiring reoperation within 90 days. Other assessments include complications related to surgery, length of hospital stay, and functional outcomes measured by the simplified modified Rankin scale. The study uses a double-blind design for patients and statisticians and plans to enroll 354 participants over approximately two years.

Researchers are evaluating the safety and effectiveness of the 3M20V.A.C.AE Peel and Place dressing when used with 3M20V.A.C.AE Therapy for treating various wound types. This study collects post-market data to better understand how well this dressing works and how safe it is for patients with open or closed wounds. The study is prospective, conducted at multiple centers, and involves a single group of participants. Participants will receive the 3M20V.A.C.AE Peel and Place dressing applied along with 3M20V.A.C.AE Therapy. The study plans to enroll about 90 subjects, each with one study wound, including 60 open wounds and 30 closed or covered wounds. Treatment includes an initial dressing application, with dressing changes as needed but no more than 7 days apart, followed by an end-of-treatment visit between 7 and 14 days after the first application. Participants will be involved for up to 20 days, beginning with a screening period up to 5 days. During the study, researchers will monitor the incidence of adverse device effects and assess wound healing, including the closure of surgical incisions and skin flaps, skin graft success, and overall wound healing rates. Safety and healing outcomes will be evaluated at 14 days, with multiple clinical visits for dressing changes and assessments.

Researchers are evaluating the effectiveness and safety of ENERGI-F703 GEL in treating diabetic foot ulcers classified as Wagner Grade 1 to Grade 2. This Phase 3, randomized, double-blind, vehicle-controlled study includes participants with ulcers of different sizes and aims to compare the gel against a vehicle control across multiple centers. The total study duration is up to 31 weeks, encompassing screening, treatment, and safety follow-up phases. Participants will be randomly assigned to receive either ENERGI-F703 GEL or a matching vehicle gel, both applied topically twice daily for 16 weeks. The study uses a web-based system to assign participants to one of the two groups. After the treatment phase, a 12-week safety follow-up is conducted to monitor participants. Initial screening lasts approximately 2 to 3 weeks before treatment begins. Throughout the study, participants undergo regular assessments including evaluation of ulcer closure rates at week 16, and monitoring of ulcer healing progress at multiple time points. Safety is tracked by recording adverse events from week 1 through week 28. Participants will have visits to assess wound status, adverse events, and overall health, with the primary outcome being the complete closure of the ulcer by week 16.

Researchers are evaluating the safety and effectiveness of Zavicefta in patients with difficult infections in the abdomen, urinary tract, and pneumonia, including infections possibly acquired during hospital stays. This observational study follows regulations by the Ministry of Food and Drug Safety (MFDS) in Korea and focuses on real-world use after Zavicefta is released in the Korean market. The study aims to collect data on adverse events and treatment responses during routine clinical practice. The study involves patients who have been given at least one dose of Zavicefta for approved infections such as complicated intra-abdominal infection, complicated urinary tract infection including pyelonephritis, hospital-acquired pneumonia including ventilator-associated pneumonia, and other infections caused by aerobic Gram-negative bacteria with limited treatment options. Patients receiving Zavicefta for the first time are included. The study period covers monitoring from the first dose and continues for at least 28 days post-treatment, with follow-up up to one year for clinical response assessment. Participants will be observed during their usual medical care while data is collected on any adverse events or drug reactions, including both expected and unexpected effects. Researchers will track the number of patients reporting adverse events and evaluate treatment outcomes such as clinical cure rates. This post-marketing surveillance study continues for six years after Zavicefta's approval to ensure ongoing safety and effectiveness monitoring in real-world settings.

Carpal Tunnel Syndrome is a common condition that causes symptoms like tingling, pain, numbness, and weakness. Surgery called carpal tunnel release is the most effective treatment. This research compares two types of sutures used to close wounds after surgery — absorbable and non-absorbable — to see if one type affects the chance of wound infection. The study is a randomized controlled trial investigating how sutures influence infections after surgery. Participants will receive carpal tunnel release surgery where the flexor retinaculum is cut to relieve pressure. After surgery, wounds will be closed using either absorbable sutures (Vicryl rapide or Safil quick) or non-absorbable sutures (Ethilon or Flexocrin). Both suture types are commonly used, but this study aims to find if one leads to fewer infections. The trial does not use masking, and participants are randomly assigned to one of the two suture groups. During the study, researchers will assess wound healing using the ASEPSIS wound score between 10 and 14 days after surgery. Patients will also record their pain using a Numeric Rating Scale for up to three weeks after surgery. Use of antibiotics, hand therapy, and any extra doctor visits will be recorded. The study is sponsored by Gelre Hospitals and includes adult participants aged 18 and older. Participation may last several weeks for follow-up and assessments.

Researchers are conducting a study called Acutelines, a large data and biobank project at the University Medical Center Groningen in the Netherlands. It focuses on patients with a wide range of acute medical conditions who present to the Emergency Department. The goal is to improve how acute diseases are recognized and treated, understand their outcomes, and support personalized medicine by collecting detailed clinical data, imaging, and biomaterials over time. Participants have their medical information, including demographics, health status, medical history, vital signs, diagnostic tests, and treatments, systematically collected. Biomaterials such as blood, urine, feces, and hair are gathered from patients who meet certain severity criteria. Data collection occurs during hospital admission, including continuous monitoring, and continues with follow-ups at 3 months, 1 year, 2 years, and 5 years after the initial emergency visit. Throughout the study, various assessments are performed, such as quality of life, physical functioning, mental health, symptoms, and hospital length of stay. Researchers collect data on mortality and other health outcomes for up to 50 years. The study uses digital tools to automate data capture and integrates information from multiple healthcare sources. Participants will be monitored closely during hospitalization and at scheduled intervals afterward to help improve understanding and treatment of acute diseases.

Researchers are evaluating the effect of adding clindamycin to the usual treatment of skin and soft tissue infections caused by Staphylococcus aureus in patients from Sierra Leone. The study aims to see if this combination leads to faster healing and fewer infection recurrences. These infections can be severe due to toxins produced by the bacteria, and clindamycin is believed to reduce these toxins. The trial compares standard treatment, usually involving anti-staphylococcal penicillin with or without surgery to drain infection, to the same treatment plus clindamycin. Clindamycin is given either orally or intravenously for 7 days, with dosing adjusted by weight. Participants receive either the standard care alone or the standard care plus clindamycin, and the study is open-label, meaning both patients and doctors know which treatment is given. Participants will be adults with confirmed Staphylococcus aureus skin infections who require systemic therapy. They will be monitored for clinical cure at 7 and 14 days, changes in inflammation, symptom resolution time, possible side effects, microbiological failure, and infections returning over 6 months. Follow-up visits may occur during hospital admission or at home, and safety and treatment outcomes will be carefully tracked throughout the study period.